Journal of Medical Physics and Applied Sciences

Radioprotective properties of the anti-cancer preparation NSC-631570 (UKRAIN)

International Conference on Nuclear Medicine & Radiation Therapy
October 01- 02 , 2018 Stockholm , Sweden

Wassil Nowicky

Nowicky Pharma/ Ukrainian Anti-Cancer Institute, Austria

ScientificTracks Abstracts: J. med phys & appl sci 2018

DOI: 10.21767/2574-285X-C1-002

Abstract

When NSC-631570 has been used in clinic, it was observed that the patients treated with this drug tolerate the concomitant radiotherapy much better. The adverse effects of this aggressive treatment modality were significantly reduced to minimal. This gave reason to study radioprotective properties of NSCâ�?631570 in the in vitro and in vivo tests. It was proven the radioprotective effect of NSCâ�?631570 was far superior compared to such of its raw materials taken separately, both measured by survival of mice irradiated by different doses and by the protection coefficient. For example, at a dose of 5.25 Gy, protection coefficient of NSCâ�?631570 was 95.0±4.6 vs 50.8±4.6 in the control. These observations suggested that the radio protective effect of UKRAIN differs significantly from such of its raw material. NSCâ�?631570 was effective in the therapy of recurring respiratory diseases in children from the Chernobyl area. A total of 38 children from areas of radiation contaminated after the chernobyl accident and suffering from recurrent respiratory diseases were included into the study. UKRAIN was administered intravenously at a dose of 5 mg twice a week, up to a total dose of 35 mg. The control group received standard therapy. In the UKRAIN treated group marked antiinflammatory effect was revealed compared to the control: normalisation of WBC count and blood sedimentation rate. The immune modulating effect of UKRAIN was indicated through the improvement in specific humoral and cellular immunity: increased the IgG concentration, the phagocytic activity of neutrophils, the number of total lymphocytes, Tlymphocytes and Thelpers, and the helpers/suppressors ratio.

Biography

Wassil Nowicky (Dipl Ing, Dr techn, DDD rh c) is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He is the Inventor of NSC-631570, the anticancer preparation on basis of celandine alkaloids. He is the Author of over 300 scientific articles dedicated to cancer research. He is a real Member of the New York Academy of Sciences, Member of the European Union for applied immunology and of the American Association for scientific progress, honorary Doctor of the Yanka Kupala State University of Grodno, doctor Honoris Causa of the Open International University for Complementary Medicine in Colombo, Honorary Member of the Austrian Society on the Name of Albert Schweizer. He has received merits of National Guild of the award of Austrian Society of sanitary, hygiene and public health services and others.

E-mail: dr.nowicky@yahoo.de